<DOC>
	<DOCNO>NCT02523768</DOCNO>
	<brief_summary>IgA nephropathy ( IgAN ) histologically define glomerulonephritis ( renal biopsy ) presence deposit immunoglobulin A ( IgA ) renal mesangium ( least 1+ ) immunofluorescence . The clinic allows exclude secondary form ( 10-15 % ) . Recurrence condition renal graft time-dependent confirm 25 50 % 10 year post-transplant . The primary immunosuppressive induction regimen currently use kidney transplantation anti-lymphocyte globulin ( GAL ) whose main target human T lymphocyte ( ATG , polyclonal ) monoclonal anti-CD25 antibody ( α chain interleukin receptor 2 surface T lymphocytes ) . Due potent prolong immunosuppressive property , ATG may prevent delay recurrence renal transplant . The aim study evaluate influence induction therapy ( ATG versus Basiliximab ) cumulative incidence 5 year ( IgAN ) recurrence first kidney transplant . This prospective , multicenter , randomize , open trial follow-up period 5 year old . Patients ATG arm receive 5 antilymphocyte globulin infusion Fresenius® ( rabbit immunoglobulin antilymphocyte human T-Fresenius® say ATG ) Day 0 Day + 4 post-transplant ( day 0 one dose 4mg / kg , day 1 one dose 4mg/kg , day2 one dose 4mgkg , day 3 one dose 3 m/kg day 4 one final dose 3 mg/kg ) patient anti-CD25 arm receive 2 dose 20 mg basiliximab ( Simulect® ) pn day 0 day 4 graft . The maintenance immunosuppressive therapy leave discretion center . The primary endpoint clinical histological recurrence IgAN define presence mesangial deposit IgA ( least 1 ) immunofluorescence biopsy graft trigger onset proteinuria 1g/j and/or microalbuminuria great 300 mg / day .</brief_summary>
	<brief_title>Prevention Recipients With Primary IgA Nephropathy Recurrence After Kidney Transplantation : ATG-F Versus Basiliximab Induction Immunosuppressive Treatment</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<criteria>Free , inform , express write . Diagnosis native kidney primary IgA glomerulonephritis biopsyproven First kidney transplantation ( one kidney ) Panel Reactive Antibody ( PRA PRA global class I class II PRA ) 50 % serum transplantation Multiorgan graft Transplants use donor limit suboptimal : donor age ≥ 70 year , donor study BIGRAS take heart beat donor ( test computer infusion ) restriction factor IgA glomerulonephritis secondary HSP ( HenochSchonlein purpura ) Systemic Lupus Erythematosus ( SLE ) alcoholic cirrhosis History cancer old 5 year advance cancer , except nonrecurrent skin cancer Infectious disease scalable : tuberculosis , HIV , Hepatitis B virus Hepatitis C virus infection viral replication / chronic hepatitis Allergy rabbit protein Severe thrombocytopenia ( &lt; 50,000 platelets/ul ) Bacterial infection , viral fungal uncontrolled therapeutically Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>